Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 3
1991 1
1992 1
1993 4
1994 6
1995 3
1996 4
1997 8
1998 7
1999 4
2000 7
2001 6
2002 9
2003 6
2004 4
2005 9
2006 11
2007 6
2008 6
2009 1
2011 2
2012 3
2013 11
2014 5
2015 5
2016 5
2017 1
2018 2
2019 2
2020 4
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Physiological reprogramming in vivo mediated by Sox4 pioneer factor activity.
Katsuda T, Sussman J, Ito K, Katznelson A, Yuan S, Li J, Merrell AJ, Takenaka N, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Katsuda T, et al. Among authors: cure h. bioRxiv [Preprint]. 2023 Feb 14:2023.02.14.528556. doi: 10.1101/2023.02.14.528556. bioRxiv. 2023. PMID: 36824858 Free PMC article. Updated. Preprint.
Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity.
Katsuda T, Sussman JH, Ito K, Katznelson A, Yuan S, Takenaka N, Li J, Merrell AJ, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Katsuda T, et al. Among authors: cure h. Nat Commun. 2024 Feb 26;15(1):1761. doi: 10.1038/s41467-024-45939-z. Nat Commun. 2024. PMID: 38409161 Free PMC article.
[Adjuvant medical treatment].
Plagne R, Chollet P, Legros M, Cure H, Ferrière JP, Bignon YJ. Plagne R, et al. Among authors: cure h. Rev Prat. 1990 Apr 1;40(10):905-8. Rev Prat. 1990. PMID: 2183339 Review. French.
[Therapeutic potential of melatonin in cancer treatment].
Abrial C, Kwiatkowski F, Chevrier R, Gachon F, Curé H, Chollet P. Abrial C, et al. Among authors: cure h. Pathol Biol (Paris). 2005 Jun;53(5):265-8. doi: 10.1016/j.patbio.2004.12.009. Epub 2005 Jan 20. Pathol Biol (Paris). 2005. PMID: 15939135 Review. French.
[Stress, cancer and circadian rhythm of melatonin].
Kwiatkowski F, Abrial C, Gachon F, Chevrier R, Curé H, Chollet P. Kwiatkowski F, et al. Among authors: cure h. Pathol Biol (Paris). 2005 Jun;53(5):269-72. doi: 10.1016/j.patbio.2004.12.018. Epub 2005 Jan 20. Pathol Biol (Paris). 2005. PMID: 15939136 Review. French.
Rapid in vivo multiplexed editing (RIME) of the adult mouse liver.
Katsuda T, Cure H, Sussman J, Simeonov KP, Krapp C, Arany Z, Grompe M, Stanger BZ. Katsuda T, et al. Among authors: cure h. Hepatology. 2023 Aug 1;78(2):486-502. doi: 10.1002/hep.32759. Epub 2022 Oct 13. Hepatology. 2023. PMID: 36037289
Neoadjuvant endocrine therapy in breast cancer.
Abrial C, Mouret-Reynier MA, Curé H, Feillel V, Leheurteur M, Lemery S, Le Bouëdec G, Durando X, Dauplat J, Chollet P. Abrial C, et al. Among authors: cure h. Breast. 2006 Feb;15(1):9-19. doi: 10.1016/j.breast.2005.07.009. Epub 2005 Oct 17. Breast. 2006. PMID: 16230013 Review.
142 results